Logo

Merrimack Gets NCI Phase I SBIR Grant for Protein Microarrays

Jan 29, 2004

NEW YORK, Jan. 29 (GenomeWeb News) - Merrimack Pharmaceuticals has received a Phase I SBIR Grant from the National Cancer Institute, the company said today.

 

Merrimack said it will use the grant, "Protein Microarrays in Cancer Drug Discovery," to develop and apply its microarray technology to apoptosis and cancer.

 

"The protein microarray research in this grant, combined with Merrimack's expertise in computational modeling and high-throughtput biology, should yield tremendous results in this difficult field," Michael Cardone, the company's director of science development, said in a statement.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.